About Us - Press Releases - TRIMEDYNE REPORTS A 33% INCREASE IN REVENUES IN THE QUARTER ENDED DEC. 31, 2004

Trimedyne
The Leader in Cost-Effective Laser Technology

Company History | Management Team | Press Releases | Contact Us | Careers

| Laser Spine Therapy Provider List |

FOR IMMEDIATE RELEASE

CONTACT: CRAIG SMITH

949.951.3800 EXT. 288

csmith@trimedyne.com

TRIMEDYNE REPORTS A 33% INCREASE IN REVENUES IN THE QUARTER ENDED DEC. 31, 2004

February 15, 2005 – Irvine, CA: TRIMEDYNE, INC. (OTCBB “TMED”) today reported a 33% increase in revenues to $1,839,000 for the quarter ended December 31, 2004, compared to revenues of $ 1,380,000 for the same quarter of the prior year.

Net profit was $173,000 or $0.01 per share for the current quarter, compared to a net profit of $165,000 or $0.01 per share in the prior year quarter. However, the profit for the prior year quarter included the benefit of $123,000 of other income, whereas other income in the current quarter was only $26,000, and R & D costs in the current quarter were twice those of the year earlier quarter, $133,000 versus $67,000.

Glenn D. Yeik, President of Trimedyne, said, “We are pleased to report a significant increase in sales of our surgical lasers in the current quarter, compared to the year ago period. While marketing expenses to introduce our new disposable devices are expected to rise in the coming months, we anticipate our revenues will increase from sales of the new products, although such cannot be assured.”

Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, financial and other information, visit Trimedyne's website http://www.trimedyne.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.

*****

Back